Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/26728
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | O’Neil, Bert | - |
dc.contributor.author | Shahda, Saf | - |
dc.date.accessioned | 2022-05-27T12:03:13Z | - |
dc.date.available | 2022-05-27T12:03:13Z | - |
dc.date.issued | 2015-12-15 | - |
dc.identifier.citation | Kanat, Ö. vd. (2015). "Targeted therapy for advanced gastric cancer: A review o current status and future prospects". World Journal of Gastrointestinal Oncology, 7(12), 401-410. | en_US |
dc.identifier.issn | 1948-5204 | - |
dc.identifier.uri | https://doi.org/10.4251/wjgo.v7.i12.401 | - |
dc.identifier.uri | https://www.wjgnet.com/1948-5204/full/v7/i12/401.htm | - |
dc.identifier.uri | http://hdl.handle.net/11452/26728 | - |
dc.description.abstract | In the West in particular, the vast majority of gastric cancer (GC) patients present with advanced-stage disease. Although combination chemotherapy is still the most important component of treatment for these patients, it confers a modest survival advantage. Recently, increased knowledge of the key molecular signaling pathways involved in gastric carcinogenesis has led to the discovery of specific molecular-targeted thera-peutic agents. Some of these agents such as trastuzumab and ramucirumab have changed the treatment paradigm for this disease. In this paper, we will summarize the current clinical status of targeted drug therapy in the management of GC. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Baishideng Publishing Group | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Angio-genesis | en_US |
dc.subject | Epidermal growth factor | en_US |
dc.subject | Gastric cancer | en_US |
dc.subject | Targeted therapy | en_US |
dc.subject | Treatment | en_US |
dc.subject | Phase-II trial | en_US |
dc.subject | Advanced esophagogastric cancer | en_US |
dc.subject | Double-blind | en_US |
dc.subject | Open-label | en_US |
dc.subject | Junction adenocarcinoma | en_US |
dc.subject | 1st-line treatment | en_US |
dc.subject | Capecitabine | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Cisplatin | en_US |
dc.subject | Combination | en_US |
dc.subject | Oncology | en_US |
dc.subject | Gastroenterology & hepatology | en_US |
dc.title | Targeted therapy for advanced gastric cancer: A review o current status and future prospects | en_US |
dc.type | Review | en_US |
dc.identifier.wos | 000422139600004 | tr_TR |
dc.identifier.scopus | 2-s2.0-85007568558 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 401 | tr_TR |
dc.identifier.endpage | 410 | tr_TR |
dc.identifier.volume | 7 | tr_TR |
dc.identifier.issue | 12 | tr_TR |
dc.relation.journal | World Journal of Gastrointestinal Oncology | en_US |
dc.contributor.buuauthor | Kanat, Özkan | - |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.identifier.pubmed | 26690491 | tr_TR |
dc.subject.wos | Oncology | en_US |
dc.subject.wos | Gastroenterology & hepatology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.contributor.scopusid | 55881548500 | tr_TR |
dc.subject.scopus | Ramucirumab; Rivoceranib; Line | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Kanat_vd_2015.pdf | 924.48 kB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License